

Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-May-2018  
Document Type: USP Monographs  
DocId: GUID-F8D39FE8-4B02-4647-8E83-B06D1006CBD6\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M14143\\_03\\_01](https://doi.org/10.31003/USPNF_M14143_03_01)  
DOI Ref: n0f5d

© 2025 USPC  
Do not distribute

# Ceftizoxime for Injection

» Ceftizoxime for Injection contains an amount of Ceftizoxime Sodium equivalent to not less than 90.0 percent and not more than 115.0 percent of the labeled amount of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ).

**Packaging and storage**—Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), [Packaging for constitution](#).

**USP REFERENCE STANDARDS (11)**—  
[USP Ceftizoxime RS](#)

**Constituted solution**—At the time of use, it meets the requirements for [Injections and Implanted Drug Products \(1\)](#), [Specific Tests](#), [Completeness and clarity of solutions](#).

**BACTERIAL ENDOTOXINS TEST (85)**—It contains not more than 0.10 USP Endotoxin Unit per mg of ceftizoxime.

**STERILITY TESTS (71)**—It meets the requirements when tested as directed for *Membrane Filtration* under *Test for Sterility of the Product to be Examined*.

**PARTICULATE MATTER IN INJECTIONS (788)**: meets the requirements for small-volume injections.

**Other requirements**—It responds to the *Identification* tests and meets the requirements for *Crystallinity*, *pH*, and [Water](#) under [Ceftizoxime Sodium](#). It meets also the requirements for [Uniformity of Dosage Units \(905\)](#) and for [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#).

**Assay**—

*pH 3.6 Buffer*, *pH 7.0 Buffer*, *Mobile phase*, *Internal standard solution*, and *Chromatographic system*—Prepare as directed in the [Assay](#) under [Ceftizoxime Sodium](#).

*Standard preparation*—Dissolve a suitable quantity of [USP Ceftizoxime RS](#), accurately weighed, in *pH 7.0 Buffer* to obtain a solution having a known concentration of about 1 mg of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ) per mL. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and mix. This *Standard preparation* contains about 0.02 mg of ceftizoxime per mL.

*Assay preparation 1* (where it is represented as being in a single-dose container)—Constitute Ceftizoxime for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling. Withdraw all of the withdrawable contents, using a suitable hypodermic needle and syringe, and dilute quantitatively with *pH 7.0 Buffer* to obtain a solution containing about 1 mg of ceftizoxime per mL. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and mix.

*Assay preparation 2* (where the label states the quantity of ceftizoxime in a given volume of constituted solution)—Constitute Ceftizoxime for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling. Dilute an accurately measured volume of the constituted solution quantitatively with *pH 7.0 Buffer* to obtain a solution containing about 1 mg of ceftizoxime per mL. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and mix.

*Procedure*—Proceed with Ceftizoxime for Injection as directed for *Procedure* in the [Assay](#) under [Ceftizoxime Sodium](#). Calculate the quantity, in mg, of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ) withdrawn from the container, or in the portion of constituted solution taken by the formula:

$$(L/D)(C)(R_U/R_S)$$

in which *L* is the labeled quantity, in mg of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ), in the container, or in the volume of constituted solution taken, and *D* is the concentration, in mg of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ) per mL, of *Assay preparation 1* or *Assay preparation 2*, based on the labeled quantity in the container or in the portion of constituted solution taken, respectively; and the extent of dilution, *C* is the concentration, in mg of ceftizoxime ( $C_{13}H_{13}N_5O_5S_2$ ) per mL, of the *Standard preparation*; and *R<sub>U</sub>* and *R<sub>S</sub>* are the peak response ratios of the ceftizoxime peak to the internal standard peak obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CEFTIZOXIME FOR INJECTION	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 45(4)

**Current DocID: GUID-F8D39FE8-4B02-4647-8E83-B06D1006CBD6\_3\_en-US**

**Previous DocID: GUID-F8D39FE8-4B02-4647-8E83-B06D1006CBD6\_1\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M14143\\_03\\_01](https://doi.org/10.31003/USPNF_M14143_03_01)**

**DOI ref: [n0f5d](#)**

OFFICIAL